Literature DB >> 19464529

The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.

Antonio Nakouzi1, Tong Zhang, Stefan Oscarson, Arturo Casadevall.   

Abstract

The Cryptococcus neoformans capsular glucuronoxylomannan (GXM) is a potential vaccine antigen that can elicit protective and non-protective antibodies. In an attempt to focus the immune response on a single antigenic component, a heptasaccharide oligosaccharide representing the major structural motif (M2) of the most common clinical isolate was synthesized and conjugated to human serum albumin (HSA). Monoclonal antibodies (mAbs) generated from mice immunized with M2-HSA produced the characteristic punctuate immunofluorescence associated with non-protective mAbs. None of the mAbs elicited by M2 immunization was opsonic. Passive administration of mAbs elicited by M2-HSA was not protective and there was no difference in the survival of mice immunized with M2-HSA and HSA. Hence, we conclude that the M2 motif represents an antigenic determinant in C. neoformans GXM that elicits non-protective responses and is not a suitable vaccine candidate. Furthermore, the results illustrate the first molecular assignment of a C. neoformans polysaccharide epitope and suggest a general strategy for the identification of GXM epitopes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464529      PMCID: PMC2932445          DOI: 10.1016/j.vaccine.2009.03.089

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity.

Authors:  Jennifer S Lam; Michael K Mansour; Charles A Specht; Stuart M Levitz
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.

Authors:  P Valadon; G Nussbaum; L F Boyd; D H Margulies; M D Scharff
Journal:  J Mol Biol       Date:  1996-08-09       Impact factor: 5.469

3.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation.

Authors:  Donatella Pietrella; Cristina Corbucci; Stefano Perito; Giovanni Bistoni; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 5.  Towards a vaccine for Cryptococcus neoformans: principles and caveats.

Authors:  Kausik Datta; Liise-anne Pirofski
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

Review 6.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

7.  Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.

Authors:  F Dromer; J Salamero; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

8.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

Review 9.  Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity.

Authors:  Anna Vecchiarelli
Journal:  Crit Rev Immunol       Date:  2007       Impact factor: 2.214

10.  FURTHER STUDIES ON IMMUNITY IN EXPERIMENTAL CRYPTOCOCCOSIS.

Authors:  D B Louria; T Kaminski; G Finkel
Journal:  J Exp Med       Date:  1963-02-28       Impact factor: 14.307

View more
  9 in total

1.  Titan cells: barriers to phagocytosis.

Authors:  Vivek Negi; Roshan Kumar; Helianthous Verma; Naseer Sangwan; Rup Lal
Journal:  Indian J Microbiol       Date:  2012-09       Impact factor: 2.461

2.  Advancing translational immunology in HIV-associated cryptococcal meningitis.

Authors:  Peter R Williamson
Journal:  J Infect Dis       Date:  2013-03-14       Impact factor: 5.226

3.  A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides.

Authors:  Anthony Bowen; Maggie P Wear; Radames J B Cordero; Stefan Oscarson; Arturo Casadevall
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

4.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

5.  A glycan FRET assay for detection and characterization of catalytic antibodies to the Cryptococcus neoformans capsule.

Authors:  Conor J Crawford; Maggie P Wear; Daniel F Q Smith; Clotilde d'Errico; Scott A McConnell; Arturo Casadevall; Stefan Oscarson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

6.  Synthesis of a Glucuronic Acid-Containing Thioglycoside Trisaccharide Building Block and Its Use in the Assembly of Cryptococcus Neoformans Capsular Polysaccharide Fragments.

Authors:  Lorenzo Guazzelli; Rebecca Ulc; Stefan Oscarson
Journal:  ChemistryOpen       Date:  2015-08-18       Impact factor: 2.911

Review 7.  Monoclonal Antibodies as Tools to Combat Fungal Infections.

Authors:  Sebastian Ulrich; Frank Ebel
Journal:  J Fungi (Basel)       Date:  2020-02-04

Review 8.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

9.  Cryptococcus neoformans Capsular GXM Conformation and Epitope Presentation: A Molecular Modelling Study.

Authors:  Michelle M Kuttel; Arturo Casadevall; Stefan Oscarson
Journal:  Molecules       Date:  2020-06-07       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.